Latest Cancer vaccine Stories
Robust Clinical Development Programs Across Sellas' Portfolio of Drugs and Biologics ZUG, Switzerland and NEW YORK, Oct.
TUBINGEN, Germany, October 14, 2014 /PRNewswire/ -- Regulatory authority approves clinical trial for Glioma Actively Personalized
SAN DIEGO, Oct. 10, 2014 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc.
Program Funded by the National Cancer Institute (NCI) CHARLOTTESVILLE, Va., Oct.
LONDON, Oct. 2, 2014 /PRNewswire/ -- This report focuses on the rising potential for the newest and most promising of cancer treatments: cancer immunotherapy.
SAN DIEGO, Sept. 25, 2014 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (OTCQB: TELKD), a clinical stage oncology drug development company, announced today that the U.S.
Ex-Vivo Manipulation of Autologous Hematopoietic Stem Cells Complements Dendritic Cell-based Vaccine Platform; Potential to Develop Single-Agent and Combination Immunotherapeutics LOS
New research report “Global Cancer Vaccines Market & Pipeline Analysis” worked out by Kuick Research is now available at MarketPublishers.com. London,
- Boehringer Ingelheim obtains exclusive global rights for development and commercialization of CureVac's investigational therapeutic cancer vaccine CV9202 INGELHEIM and TUBINGEN, Germany,
"PIM" Designation For DCVax-L Is First Step In 2-Step Process for Early Access Approval BETHESDA, Md., Sept.
- a meat pie that is usually eaten at Christmas in Quebec